AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Additional_JJ
Information_NOMZ
www_NN
._.
com_NN
139_CD
Additional_JJ
Information_NOMZ
History_NN
and_PHC
development_NOMZ
of_PIN
the_DT
Company_NN
Directors_NN
are_VPRT [PASS]
not_XX0
required_VBN [SUAV]
to_TO
retire_VB
at_PIN
a_DT
For_PIN
all_QUAN
general_JJ
meetings_GER
,_,
a_DT
quorum_NN
of_PIN
two_CD
particular_JJ
age_NN
._.
shareholders_NN
present_VPRT
in_PIN
person_NN
or_CC
by_PIN
proxy_NN
is_VPRT [PASS]
required_VBN [SUAV]
._.
AstraZeneca_NN
PLC_NN
was_VBD [PASS]
incorporated_VBN
in_PIN
England_NN
and_PHC
Wales_NN
on_PIN
17_CD
June_NN
1992_CD
under_IN
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO [SPIN]
beneficially_RB
own_VB
the_DT
Companies_NN
Act_NN
1985_CD
._.
It_PIT
is_VPRT [BEMA]
a_DT
public_JJ
limited_JJ
Ordinary_NN
Shares_NN
in_PIN
the_DT
Company_NN
of_PIN
an_DT
Shareholders_NN
and_CC
their_TPP3
duly_RB
appointed_VBN
company_NN
domiciled_VBD
in_PIN
the_DT
UK_NN
._.
The_DT
aggregate_JJ
nominal_JJ
amount_NN
of_PIN
$_$
125_CD
._.
At_PIN
proxies_NN
and_CC
corporate_JJ
representatives_NN
are_VPRT [PASS]
Companys_NN
registered_VBD
number_NN
is_VPRT [BEMA]
2723534_CD
present_JJ
,_,
this_DEMP
means_VPRT [PRIV] [THATD]
they_TPP3
must_NEMD
own_VB
at_PIN
least_JJ
entitled_VBN
to_TO
be_VB [PASS]
admitted_VBN [PUBV]
to_PIN
general_JJ
meetings_GER
._.
and_ANDC
its_PIT
registered_JJ
office_NN
is_VPRT [BEMA]
at_PIN
15_CD
Stanhope_NN
500_CD
shares_NN
._.
Gate_NN
,_,
London_NN
W1K_NN
1LN_NN
telephone_NN
44_CD
Limitations_NOMZ
on_PIN
the_DT
rights_NN
to_TO
own_VB
shares_NN
0_CD
20 7304 5000_CD
._.
From_PIN
February_NN
1993_CD
until_IN
Rights_NN
,_,
preferences_NN
and_PHC
restrictions_NOMZ
There_EX
are_VPRT
no_SYNE
limitations_NOMZ
on_PIN
the_DT
rights_NN
to_TO
own_VB
April_NN
1999_CD
,_,
the_DT
Company_NN
was_VBD [PASS]
called_VBN
Zeneca_NN
attaching_VBG [WZPRES]
to_PIN
shares_NN
shares_NN
._.
On_PIN
6_CD
April_NN
1999_CD
,_,
the_DT
Company_NN
The_DT
share_NN
capital_NN
of_PIN
the_DT
Company_NN
is_VPRT [PASS]
divided_VBN
changed_VBD
its_PIT
name_NN
to_PIN
AstraZeneca_NN
PLC._NN
._.
into_PIN
2,400,000,000_CD
Ordinary_NN
Shares_NN
with_PIN
a_DT
ShareGift_NN
nominal_JJ
value_NN
of_PIN
$_$
0.25_CD
each_QUAN
and_CC
50,000_CD
The_DT
Company_NN
was_VBD [PASS]
formed_VBN
when_RB
the_DT
Redeemable_JJ
Preference_NN
Shares_NN
with_PIN
a_DT
AstraZeneca_NN
welcomes_VPRT
and_PHC
values_VPRT
all_QUAN
its_PIT
pharmaceutical_JJ
,_,
agrochemical_NN
and_PHC
specialty_NN
nominal_JJ
value_NN
of_PIN
1.00_CD
each_QUAN
._.
The_DT
rights_NN
and_PHC
shareholders_NN
,_,
no_SYNE
matter_NN
how_RB
many_QUAN
or_CC
how_RB
chemical_JJ
businesses_NOMZ
of_PIN
Imperial_NN
Chemical_NN
restrictions_NOMZ
attaching_VBG [WZPRES]
to_PIN
the_DT
Redeemable_JJ
few_QUAN
shares_NN
they_TPP3
own_VPRT
._.
However_CONJ
,_,
shareholders_NN
Industries_NN
PLC_NN
were_VBD [PASS]
demerged_VBN
in_PIN
1993_CD
._.
In_PIN
Preference_NN
Shares_NN
differ_VPRT
from_PIN
those_DEMP
attaching_VBG
who_WP
have_VPRT
only_DWNT
a_DT
small_JJ
number_NN
of_PIN
shares_NN
1999_CD
,_,
the_DT
Company_NN
sold_VBD
the_DT
specialty_NN
to_PIN
Ordinary_NN
Shares_NN
as_IN
follows_VPRT
:_:
whose_WPS
value_NN
makes_VPRT
it_PIT
uneconomic_JJ
to_TO
sell_VB
chemical_NN
business_NOMZ
._.
Also_RB
in_PIN
1999_CD
,_,
the_DT
them_TPP3
,_,
either_RB
now_TIME
or_CC
at_PIN
some_QUAN
stage_NN
in_PIN
the_DT
Company_NN
merged_VBD
with_PIN
Astra_NN
AB_NN
of_PIN
Sweden_NN
._.
the_DT
Redeemable_NN
Preference_NN
Shares_NN
carry_VPRT
future_JJ
,_,
may_POMD
wish_VB
to_TO
consider_VB [PRIV]
donating_VBG
them_TPP3
In_PIN
2000_CD
,_,
it_PIT
demerged_VBD
the_DT
agrochemical_NN
no_SYNE
rights_NN
to_TO
receive_VB
dividends_NN
:_:
to_PIN
charity_NOMZ
through_PIN
ShareGift_NN
,_,
an_DT
independent_JJ
business_NOMZ
and_CC
merged_VBD
it_PIT
with_PIN
the_DT
similar_JJ
charity_NOMZ
share_NN
donation_NOMZ
scheme_NN
._.
One_CD
of_PIN
the_DT
agribusiness_NOMZ
of_PIN
Novartis_NN
AG_NN
to_TO
form_VB
a_DT
new_JJ
the_DT
holders_NN
of_PIN
Redeemable_JJ
Preference_NN
advantages_NN
of_PIN
the_DT
scheme_NN
is_VPRT
that_DEMO
there_EX
is_VPRT
no_SYNE
company_NN
called_VBD
Syngenta_NN
AG_NN
._.
Shares_NN
have_VPRT
no_SYNE
rights_NN
to_TO
receive_VB
notices_NN
gain_VB
or_CC
loss_NN
for_PIN
capital_NN
gains_NN
tax_NN
purposes_NN
on_PIN
of_PIN [STPR]
,_,
attend_VB
or_CC
vote_VB [SUAV]
at_PIN
general_JJ
meetings_GER
gifts_NN
of_PIN
shares_NN
through_PIN
ShareGift_NN
and_CC
it_PIT
may_POMD
The_DT
Company_NN
owns_VPRT
and_PHC
operates_VPRT
numerous_JJ
except_PIN
in_PIN
certain_JJ
limited_JJ
circumstances_NN
:_:
now_DPAR
also_RB
be_VB [BEMA]
possible_PRED
to_TO
obtain_VB
income_NN
tax_NN
R&D_NN
,_,
production_NOMZ
and_PHC
marketing_GER
facilities_NOMZ
they_TPP3
have_VPRT
one_CD
vote_NN
for_PIN
every_QUAN
50,000_CD
relief_NN
on_PIN
the_DT
donation_NOMZ
._.
Its_PIT
corporate_JJ
headquarters_NN
are_VPRT [BEMA]
at_PIN
Redeemable_JJ
Preference_NN
Shares_NN
held_VBD [PRIV]
:_:
about_IN
ShareGift_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
on_PIN
its_PIT
website_NN
,_,
15_CD
Stanhope_NN
Gate_NN
,_,
London_NN
,_,
W1K_NN
1LN_NN
and_CC
its_PIT
www_NN
._.
org_NN
,_,
or_CC
by_PIN
contacting_VBG
R&D_NN
headquarters_NN
are_VPRT [BEMA]
at_PIN
SE-151_CD
85_CD
on_PIN
a_DT
distribution_NOMZ
of_PIN
assets_NN
of_PIN
the_DT
ShareGift_NN
on_PIN
020 7337 0501_CD
or_CC
at_PIN
46_CD
Sdertlje_NN
,_,
Sweden_NN
._.
Company_NN
,_,
on_PIN
a_DT
winding-up_NN
or_CC
other_JJ
Grosvenor_NN
Street_NN
,_,
London_NN
W1K_NN
3HN_NN
._.
More_EMPH
return_NN
of_PIN
capital_NN
subject_NN
to_PIN
certain_JJ
information_NOMZ
about_IN
the_DT
tax_NN
position_NOMZ
on_PIN
gifts_NN
of_PIN
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
exceptions_NOMZ
,_,
the_DT
holders_NN
of_PIN
Redeemable_JJ
shares_NN
to_PIN
ShareGift_NN
can_POMD
be_VB [PASS]
obtained_VBN
from_PIN
the_DT
Preference_NN
Shares_NN
have_VPRT
priority_NOMZ
over_IN
the_DT
Inland_NN
Revenue_NN
whose_WPS [WHOBJ]
website_JJ
address_NN
is_VPRT
Objects_NN
holders_NN
of_PIN
Ordinary_NN
Shares_NN
to_TO
receive_VB
the_DT
www_NN
._.
The_DT
share_NN
As_IN
is_VPRT [BEMA]
typical_PRED
of_PIN
companies_NN
registered_VBN [WZPAST]
in_PIN
capital_NN
paid_VBN
up_RP
on_PIN
those_DEMO
shares_NN
:_:
and_ANDC
transfer_VB
form_NN
needed_VBN
to_TO
make_VB
a_DT
donation_NOMZ
may_POMD
England_NN
and_PHC
Wales_NN
,_,
the_DT
Companys_NN
objects_NN
,_,
be_VB [PASS]
obtained_VBN
from_PIN
the_DT
AstraZeneca_NN
Registrar_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
detailed_VBN
in_PIN
the_DT
Memorandum_NN
of_PIN
subject_JJ
to_PIN
the_DT
provisions_NN
of_PIN
the_DT
Lloyds_NN
TSB_NN
Registrars_NN
whose_WPS [WHOBJ]
address_NN
can_POMD
be_VB
Association_NOMZ
,_,
are_VPRT [BEMA]
broad_PRED
and_PHC
wide-ranging_PRED
and_CC
Companies_NN
Act_NN
1985_CD
,_,
the_DT
Company_NN
has_VPRT [PEAS]
found_VBN [PRIV]
on_PIN
page_NN
129_CD
._.
ShareGift_NN
is_VPRT [PASS]
administered_VBN
include_VPRT
manufacturing_GER
,_,
distributing_GER
and_CC
the_DT
right_NN
to_TO
redeem_VB
the_DT
Redeemable_JJ
by_PIN
The_DT
Orr_NN
Mackintosh_NN
Foundation_NOMZ
,_,
trading_GER
pharmaceutical_JJ
products_NN
._.
Preference_NN
Shares_NN
at_PIN
any_QUAN
time_NN
on_PIN
giving_VBG
registered_VBN
charity_NOMZ
number_NN
1052686_CD
._.
not_XX0
less_JJ
than_PIN
seven_CD
days_NN
written_VBN [PUBV]
notice_NN
._.
Directors_NN
The_DT
Unclaimed_NN
Assets_NN
Register_NN
Subject_NN
to_PIN
certain_JJ
exceptions_NOMZ
,_,
Directors_NN
do_VPRT [PROD]
Action_NOMZ
necessary_JJ
to_TO
change_VB
the_DT
rights_NN
of_PIN
not_XX0
have_VB
power_NN
to_TO
vote_VB [SUAV]
at_PIN
Board_NN
Meetings_GER
on_PIN
shareholders_NN
AstraZeneca_NN
supplies_VPRT
unclaimed_JJ
dividend_NN
matters_NN
in_PIN
which_WDT [PIRE]
they_TPP3
have_VPRT
a_DT
material_NN
interest_NN
._.
In_PIN
order_NN
to_TO
vary_VB
the_DT
rights_NN
attached_VBN [WZPAST]
to_PIN
any_QUAN
data_NN
to_PIN
the_DT
Unclaimed_NN
Assets_NN
Register_NN
UAR_NN
class_NN
of_PIN
shares_NN
,_,
the_DT
consent_NN
in_PIN
writing_GER
of_PIN
the_DT
which_WDT
provides_VPRT
investors_NN
who_WP [WHSUB]
have_VPRT [PEAS]
lost_VBN
track_NN
The_DT
quorum_NN
for_PIN
meetings_GER
of_PIN
the_DT
Board_NN
of_PIN
holders_NN
of_PIN
three_CD
quarters_NN
in_PIN
nominal_JJ
value_NN
of_PIN
of_PIN
shareholdings_GER
with_PIN
an_DT
opportunity_NOMZ
to_PIN
Directors_NN
is_VPRT [BEMA]
a_DT
majority_NOMZ
of_PIN
the_DT
full_JJ
Board_NN
,_,
of_PIN
the_DT
issued_VBN
shares_NN
of_PIN
that_DEMO
class_NN
or_CC
the_DT
sanction_NOMZ
search_NN
the_DT
UARs_NN
database_NN
of_PIN
unclaimed_JJ
whom_WP
at_PIN
least_JJ
four_CD
must_NEMD
be_VB [BEMA]
Non-Executive_PRED
of_PIN
an_DT
extraordinary_JJ
resolution_NOMZ
passed_VBN [WZPAST]
at_PIN
a_DT
financial_JJ
assets_NN
on_PIN
payment_NOMZ
of_PIN
a_DT
small_JJ
,_,
fixed_JJ
Directors_NN
._.
In_PIN
the_DT
absence_NN
of_PIN
a_DT
quorum_NN
,_,
the_DT
general_JJ
meeting_GER
of_PIN
such_JJ
holders_NN
is_VPRT [PASS]
required_VBN [SUAV]
._.
The_DT
UAR_NN
donates_VPRT
part_NN
of_PIN
the_DT
search_NN
fee_NN
Directors_NN
do_VPRT
not_XX0
have_VB
power_NN
to_TO
determine_VB [SUAV] [PRIV]
to_PIN
charity_NOMZ
._.
The_DT
UAR_NN
can_POMD
be_VB [PASS]
contacted_VBN
at_PIN
compensation_NOMZ
arrangements_NOMZ
for_PIN
themselves_TPP3
Annual_JJ
general_JJ
meetings_GER
and_PHC
Leconfield_NN
House_NN
,_,
Curzon_NN
Street_NN
,_,
London_NN
or_CC
any_QUAN
member_NN
of_PIN
the_DT
Board_NN
._.
extraordinary_JJ
general_JJ
meetings_GER
W1J_NN
5JA_NN
and_CC
at_PIN
www_NN
._.
Annual_JJ
general_JJ
meetings_GER
and_CC
extraordinary_JJ
The_NN
Board_NN
of_PIN
Directors_NN
may_POMD
exercise_VB
all_QUAN
the_DT
general_JJ
meetings_GER
where_RB
a_DT
special_JJ
resolution_NOMZ
is_VPRT
powers_NN
of_PIN
the_DT
Company_NN
to_TO
borrow_VB
money_NN
._.
to_TO
be_VB [PASS]
passed_VBN
or_CC
a_DT
Director_NN
is_VPRT
to_TO
be_VB [PASS]
appointed_VBN
Variation_NOMZ
of_PIN
these_DEMP
borrowing_VBG
powers_NN
would_PRMD
require_VB [SUAV] [THATD]
21_CD
clear_JJ
days_NN
notice_VPRT [PRIV]
to_PIN
shareholders_NN
._.
require_VB [SUAV]
the_DT
passing_GER
of_PIN
a_DT
special_JJ
resolution_NOMZ
of_PIN
All_QUAN
other_JJ
extraordinary_JJ
general_JJ
meetings_GER
the_DT
Companys_NN
shareholders_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Cross_NN
Reference_NN
to_PIN
Form_NN
20-F_JJ
www_NN
._.
com_NN
140_CD
Cross_NN
Reference_NN
to_PIN
Form_NN
20-F_JJ
The_DT
information_NOMZ
in_PIN
this_DEMO
document_NOMZ
that_DEMP
is_VPRT [PASS]
referenced_VBN
Item_NN
Page_NN
on_PIN
this_DEMO
page_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
Annual_JJ
Report_NN
on_PIN
3_CD
Key_NN
Information_NOMZ
Form_NN
20-F_NN
for_PIN
2002_CD
2002_CD
Form_NN
20-F_NN
and_CC
is_VPRT [PASS]
filed_VBN
A._NN
Selected_NN
financial_JJ
data_NN
with_PIN
the_DT
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
SEC_NN
._.
Financial_NN
Highlights_NN
2_CD
The_DT
2002_CD
Form_NN
20-F_NN
is_VPRT [BEMA]
the_DT
only_DWNT
document_NOMZ
intended_VBN [SUAV]
Group_NN
Financial_NN
Record_NN
123_CD
to_TO
be_VB [BYPA]
incorporated_VBN
by_PIN
reference_NN
into_PIN
any_QUAN
filings_GER
by_PIN
Shareholder_NN
Information_NOMZ
126_CD
AstraZeneca_NN
under_IN
the_DT
Securities_NOMZ
Act_NN
of_PIN
1933_CD
,_,
as_IN
D._NN
Risk_NN
factors_NN
134_CD
amended_VBN
._.
References_NN
to_PIN
major_JJ
headings_GER
include_VPRT
all_QUAN
information_NOMZ
under_IN
such_JJ
major_JJ
headings_GER
,_,
including_VBG [PRESP]
4_CD
Information_NOMZ
on_PIN
the_DT
Company_NN
subheadings_GER
._.
History_NN
and_PHC
development_NOMZ
of_PIN
the_DT
Company_NN
139_CD
only_DWNT
the_DT
information_NOMZ
contained_VBN
under_IN
such_JJ
Note_NN
11_CD
Tangible_JJ
fixed_JJ
assets_NN
78_CD
subheadings_GER
._.
Graphs_NN
are_VPRT [PASS]
not_XX0
included_VBN
unless_COND
Note_NN
26_CD
Acquisitions_NOMZ
of_PIN
subsidiaries_NN
and_PHC
purchases_NN
of_PIN
minority_NOMZ
interests_NN
90_CD
specifically_RB
identified_VBN
opposite_PIN [STPR]
._.
The_DT
2002_CD
Form_NN
20-F_JJ
Note_NN
28_CD
Disposals_NN
91_CD
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
approved_VBN
or_CC
disapproved_VBN
by_PIN
the_DT
SEC_NN
B._NN
Business_NOMZ
overview_VBD
nor_SYNE
has_VPRT
the_DT
SEC_NN
passed_VBD
comment_NOMZ
upon_PIN
the_DT
Operational_NN
Review_NN
8_CD
accuracy_NN
or_CC
adequacy_NN
of_PIN
the_DT
2002_CD
Form_NN
20-F_NN
._.
The_DT
C._NN
Organisational_NN
structure_NN
2002_CD
Form_NN
20-F_NN
filed_VBN [WZPAST]
with_PIN
the_DT
SEC_NN
may_POMD
contain_VB
Directors_NN
Report_NN
Principal_NN
activities_NOMZ
44_CD
modified_VBN
information_NOMZ
and_CC
may_POMD
be_VB [PASS]
updated_VBN
from_PIN
time_NN
Note_NN
1_CD
Composition_NOMZ
of_PIN
the_DT
Group_NN
65_CD
to_PIN
time_NN
._.
Principal_NN
Subsidiaries_NN
,_,
Joint_NN
Ventures_NN
and_PHC
Associates_NN
112_CD
D._NN
Property_NN
,_,
plants_NN
and_PHC
equipment_NOMZ
Operational_NN
Review_NN
Main_NN
Facilities_NOMZ
26_CD
5_CD
Operating_GER
and_PHC
Financial_NN
Review_NN
and_PHC
Prospects_NN
A-D_NN
._.
Financial_NN
Review_NN
30_CD
6_CD
Directors_NN
,_,
Senior_NN
Management_NOMZ
and_PHC
Employees_NN
A._NN
Directors_NN
and_CC
senior_JJ
management_NOMZ
Board_NN
of_PIN
Directors_NN
and_PHC
Officers_NN
of_PIN
the_DT
Company_NN
6_CD
B._NN
Compensation_NOMZ
Directors_NN
Remuneration_NOMZ
Report_NN
49_CD
C._NN
Board_NN
practices_NN
Board_NN
of_PIN
Directors_NN
and_PHC
Officers_NN
of_PIN
the_DT
Company_NN
6_CD
Directors_NN
Remuneration_NOMZ
Report_NN
49_CD
Directors_NN
Report_NN
44_CD
D._NN
Employees_NN
Note_NN
10_CD
Segment_NOMZ
information_NOMZ
,_,
employees_NN
76_CD
Directors_NN
Report_NN
Employees_NN
47_CD
E._NN
Share_NN
ownership_NN
Directors_NN
Remuneration_NOMZ
Report_NN
Directors_NN
Interests_NN
in_PIN
Shares_NN
53_CD
7_CD
Major_JJ
Shareholders_NN
and_PHC
Related_NN
Party_NN
Transactions_NOMZ
A._NN
Major_NN
shareholders_NN
Shareholder_NN
Information_NOMZ
Major_NN
shareholdings_GER
128_CD
B._NN
Related_NN
party_NN
transactions_NOMZ
Shareholder_NN
Information_NOMZ
Related_VBN
party_NN
transactions_NOMZ
129_CD
Note_NN
36_CD
Statutory_NN
and_CC
other_JJ
information_NOMZ
107_CD
8_CD
Financial_NN
Information_NOMZ
A._NN
Consolidated_NN
statements_NOMZ
and_CC
other_JJ
financial_JJ
information_NOMZ
Financial_NN
Statements_NOMZ
excluding_VBG [WZPRES]
Directors_NN
responsibilities_NOMZ
on_PIN
page_NN
56_CD
and_CC
Auditors_NN
opinion_NN
on_PIN
page_NN
57_CD
58_CD
B._NN
Significant_NN
changes_NN
n_VPRT
a_DT
9_CD
The_DT
Offer_NN
and_PHC
Listing_GER
A4_NN
._.
Price_NN
history_NN
of_PIN
stock_NN
listed_VBN
Shareholder_NN
Information_NOMZ
126_CD
C._NN
Markets_NN
Shareholder_NN
Information_NOMZ
127_CD
10_CD
Additional_JJ
Information_NOMZ
B._NN
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
139_CD
C._NN
Material_NN
contracts_NN
n_VPRT
a_DT
D._NN
Exchange_NN
controls_VPRT
131_CD
E._NN
Taxation_NOMZ
130_CD
H._NN
Documents_NOMZ
on_PIN
display_NN
129_CD
I._NN
Subsidiary_NN
information_NOMZ
112_CD
11_CD
Quantitative_JJ
and_PHC
Qualitative_JJ
Disclosures_NN
about_IN
Market_NN
Risk_NN
Financial_NN
Policies_NN
Treasury_NN
35_CD
13_CD
Defaults_NN
,_,
Dividend_NN
Arrearages_NN
and_PHC
Delinquencies_NN
n_VPRT
a_DT
14_CD
Material_NN
Modifications_NOMZ
to_PIN
the_DT
Rights_NN
of_PIN
Security_NOMZ
Holders_NN
and_PHC
Use_NN
of_PIN
Proceeds_NN
n_VPRT
a_DT
15_CD
Controls_NN
and_PHC
Procedures_NN
Directors_NN
Report_NN
Audit_NN
Committee_NN
,_,
Internal_NN
Controls_NN
and_PHC
Management_NOMZ
of_PIN
Risk_NN
46_CD
18_CD
Financial_NN
Statements_NOMZ
Financial_NN
Statements_NOMZ
excluding_VBG [WZPRES]
Directors_NN
responsibilities_NOMZ
on_PIN
page_NN
56_CD
and_CC
Auditors_NN
opinion_NN
on_PIN
page_NN
57 58 694617_CD
Inner_NN
Covers_NN
2_CD
19_CD
03_CD
2:51_CD
pm_NN
Page_NN
1_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
www_NN
._.
com_NN
Contents_NN
Key_NN
Achievements_NOMZ
01_CD
Trade_NN
marks_NN
Trade_NN
marks_NN
of_PIN
the_DT
AstraZeneca_NN
group_NN
Financial_NN
Highlights_NN
02_CD
of_PIN
companies_NN
appear_VPRT [SMP]
throughout_PIN
this_DEMO
document_NOMZ
Chairmans_NN
Statement_NOMZ
04_CD
in_PIN
italics_NN
._.
AstraZeneca_NN
,_,
the_DT
AstraZeneca_NN
Chief_NN
Executives_NN
Review_NN
05_CD
logotype_NN
and_CC
the_DT
AstraZeneca_NN
symbol_NN
are_VPRT [BEMA]
all_QUAN
trade_NN
marks_NN
of_PIN
the_DT
AstraZeneca_NN
group_NN
of_PIN
Board_NN
of_PIN
Directors_NN
06_CD
companies_NN
._.
Operational_JJ
Review_NN
Use_NN
of_PIN
terms_NN
In_PIN
this_DEMO
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
,_,
Strategy_NN
08_CD
unless_COND
the_DT
context_NN
otherwise_CONJ
requires_VPRT [SUAV]
,_,
Key_NN
Product_NN
Summary_NN
09_CD
AstraZeneca_NN
,_,
the_DT
Group_NN
,_,
the_DT
Company_NN
,_,
Global_NN
Market_NN
Overview_NN
10_CD
we_FPP1
,_,
us_FPP1
and_CC
our_FPP1
refer_VPRT
to_PIN
AstraZeneca_NN
PLC_NN
and_CC
its_PIT
consolidated_JJ
entities_NOMZ
._.
Gastrointestinal_NN
11_CD
Cardiovascular_NN
12_CD
Cautionary_JJ
statement_NOMZ
regarding_VBG [WZPRES]
forwardOncology_NN
13_CD
looking_VBG
statements_NOMZ
In_PIN
order_NN
to_TO
utilise_VB
the_DT
safe_JJ
harbor_NN
provisions_NN
of_PIN
Infection_NOMZ
14_CD
the_DT
US_FPP1
Private_NN
Securities_NOMZ
Litigation_NOMZ
Reform_NN
Act_NN
Respiratory_NN
and_PHC
Inflammation_NOMZ
15_CD
1995_CD
,_,
we_FPP1
are_VPRT
providing_VBG
the_DT
following_VBG
cautionary_JJ
Central_NN
Nervous_NN
System_NN
16_CD
statement_NOMZ
:_:
This_DEMO
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
contains_VPRT
certain_JJ
forward-looking_JJ
Pain_NN
Control_NN
17_CD
statements_NOMZ
about_IN
AstraZeneca_NN
._.
Although_CONC
we_FPP1
Geographic_JJ
Review_NN
18_CD
believe_VPRT [PRIV] [THATD]
our_FPP1
expectations_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
Research_NN
and_PHC
Development_NOMZ
21_CD
reasonable_JJ
assumptions_NOMZ
,_,
any_QUAN
forward-looking_JJ
statements_NOMZ
may_POMD
be_VB [BYPA]
influenced_VBN
by_PIN
factors_NN
that_TOBJ
Development_NOMZ
Pipeline_NN
22_CD
could_POMD
cause_VB
actual_JJ
outcomes_NN
and_PHC
results_NN
to_TO
be_VB
Commercialisation_NOMZ
and_PHC
Portfolio_NN
materially_RB
different_JJ
from_PIN
those_DEMP
predicted_VBN [PUBV]
._.
We_FPP1
Management_NOMZ
24_CD
identify_VB
the_DT
forward-looking_JJ
statements_NOMZ
by_PIN
using_VBG
Supply_NN
and_PHC
Manufacturing_GER
25_CD
the_DT
words_NN
anticipates_VPRT [PRIV]
,_,
believes_VPRT [PRIV]
,_,
expects_VPRT [PRIV]
,_,
intends_VPRT [SUAV]
and_CC
similar_JJ
expressions_NN
in_PIN
such_JJ
Other_JJ
Businesses_NOMZ
26_CD
statements_NOMZ
._.
These_DEMO
forward-looking_JJ
statements_NOMZ
Main_NN
Facilities_NOMZ
26_CD
are_VPRT [BEMA]
subject_PRED
to_PIN
numerous_JJ
risks_NN
and_PHC
uncertainties_NN
._.
Intellectual_NN
Property_NN
27_CD
Important_JJ
factors_NN
that_TSUB
could_POMD
cause_VB
actual_JJ
results_NN
to_TO
differ_VB
materially_RB
from_PIN
those_DEMP
contained_VBN
in_PIN
Industry_NN
Regulation_NOMZ
27_CD
forward-looking_GER
statements_NOMZ
,_,
certain_JJ
of_PIN
which_WDT [PIRE]
are_VPRT [BEMA]
Corporate_JJ
Responsibility_NOMZ
29_CD
beyond_IN
our_FPP1
control_NN
,_,
include_VPRT
,_,
among_PIN
other_JJ
Financial_NN
Review_NN
30_CD
things_NN
:_:
the_DT
loss_NN
or_CC
expiration_NOMZ
of_PIN
patents_NN
,_,
marketing_GER
exclusivity_NOMZ
or_CC
trade_NN
marks_NN
:_:
exchange_NN
Directors_NN
Report_NN
44_CD
rate_NN
fluctuations_NOMZ
:_:
the_DT
risk_NN
that_TOBJ
R&D_NN
will_PRMD
not_XX0
yield_VB
Directors_NN
Remuneration_NOMZ
Report_NN
49_CD
new_JJ
products_NN
that_TSUB
achieve_VPRT
commercial_JJ
success_NN
:_:
the_DT
impact_NN
of_PIN
competition_NOMZ
,_,
price_NN
controls_NN
and_PHC
price_NN
reductions_NOMZ
:_:
taxation_NOMZ
risks_NN
:_:
the_DT
risk_NN
of_PIN
Financial_NN
Statements_NOMZ
substantial_JJ
product_NN
liability_NOMZ
claims_NN
:_:
the_DT
impact_NN
Contents_VPRT
55_CD
of_PIN
any_QUAN
failure_NN
by_PIN
third_JJ
parties_NN
to_TO
supply_VB
materials_NN
Financial_NN
Statements_NOMZ
and_PHC
Notes_NN
Relating_GER
or_CC
services_NN
:_:
the_DT
risk_NN
of_PIN
delay_NN
to_PIN
new_JJ
product_NN
launches_NN
:_:
the_DT
difficulties_NN
of_PIN
obtaining_VBG
and_CC
to_PIN
the_DT
Financial_NN
Statements_NOMZ
56_CD
maintaining_VBG [PUBV]
governmental_JJ
approvals_NN
for_PIN
Principal_NN
Subsidiaries_NN
,_,
Joint_NN
Ventures_NN
products_NN
:_:
and_ANDC
the_DT
risk_NN
of_PIN
environmental_JJ
and_CC
Associates_NN
112_CD
liabilities_NOMZ
._.
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
113_CD
Statements_NOMZ
of_PIN
competitive_JJ
position_NOMZ
Group_NN
Financial_NN
Record_NN
UK_NN
GAAP_NN
123_CD
Except_PIN
as_IN
otherwise_CONJ
stated_VBN [PUBV]
,_,
market_NN
information_NOMZ
Group_NN
Financial_NN
Record_NN
US_FPP1
GAAP_NN
125_CD
in_PIN
this_DEMO
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Shareholder_NN
Information_NOMZ
126_CD
regarding_VBG
the_DT
position_NOMZ
of_PIN
our_FPP1
business_NOMZ
or_CC
products_NN
relative_JJ
to_PIN
its_PIT
or_CC
their_TPP3
competition_NOMZ
is_VPRT
Risk_NN
Factors_NN
134_CD
based_VBN
upon_PIN
published_VBN
statistical_JJ
data_NN
for_PIN
the_DT
AstraZeneca_NN
Code_NN
of_PIN
Conduct_NN
137_CD
12_CD
months_NN
ended_VBD
30_CD
September_NN
2002_CD
,_,
or_CC
the_DT
Additional_JJ
Information_NOMZ
139_CD
month_NN
of_PIN
November_NN
2002_CD
,_,
obtained_VBN [PASTP]
from_PIN
IMS_NN
Health_NN
,_,
a_DT
leading_VBG
supplier_NN
of_PIN
statistical_JJ
data_NN
to_PIN
Cross_NN
Reference_NN
to_PIN
Form_NN
20-F_JJ
140_CD
the_DT
pharmaceutical_JJ
industry_NN
._.
Except_PIN
as_IN
otherwise_CONJ
stated_VBN [PUBV]
,_,
this_DEMO
market_NN
share_NN
and_PHC
industry_NN
data_NN
from_PIN
IMS_NN
Health_NN
has_VPRT [PEAS]
been_VBN [BYPA]
derived_VBN
by_PIN
comparing_VBG
our_FPP1
sales_NN
revenue_NN
to_PIN
competitors_NN
and_CC
total_JJ
market_NN
sales_NN
revenues_NN
for_PIN
that_DEMO
period_NN
._.
Statements_NOMZ
of_PIN
growth_NN
rates_NN
Except_PIN
as_IN
otherwise_CONJ
stated_VBN [PUBV]
,_,
growth_NN
rates_NN
in_PIN
this_DEMO
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
are_VPRT [PASS]
given_VBN
at_PIN
constant_JJ
exchange_NN
rates_NN
CER_NN
._.
AstraZeneca_NN
website_JJ
Information_NOMZ
on_PIN
our_FPP1
website_NN
,_,
www_NN
._.
com_NN
,_,
does_VPRT
not_XX0
form_VB
part_NN
of_PIN
this_DEMO
document_NOMZ
._.
AstraZeneca_NN
PLC_NN
2003_CD
AstraZeneca_NN
Annual_JJ
Report_NN
&_CC
Form_NN
20-F_JJ
2002 694617_CD
Outer_NN
Covers_NN
2_CD
19_CD
03_CD
2:50_CD
pm_NN
Page_NN
1_CD
www_NN
._.
com_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Registered_NN
office_NN
and_CC
corporate_JJ
headquarters_NN
:_:
AstraZeneca_NN
PLC_NN
15_CD
Stanhope_NN
Gate_NN
London_NN
W1K_NN
1LN_NN
UK_NN
Tel_NN
:_:
44_CD
0_CD
20 7304 5000_CD
Fax_NN
:_:
44_CD
0_CD
20 7304 5183_CD
R&D_NN
headquarters_NN
address_NN
:_:
AstraZeneca_NN
R&D_NN
Sdertlje_NN
SE-151_NN
85_CD
Sdertlje_NN
Sweden_NN
Tel_NN
:_:
46_CD
0_CD
8_CD
553_CD
260_CD
00_CD
Fax_NN
:_:
46_CD
0_CD
8_CD
553_CD
290_CD
00_CD
Investor_NN
relations_NOMZ
contacts_NN
:_:
UK_NN
and_PHC
Sweden_NN
:_:
As_IN
above_PLACE
or_CC
e-mail_VB
:_:
investor-relations@astrazeneca_NN
._.
com_NN
US_FPP1
:_:
Were_VBD
Investor_NN
Relations_NOMZ
AstraZeneca_NN
LP_NN
1800_CD
Concord_NN
Pike_NN
PO_NN
Box_NN
15438_CD
Wilmington_NN
fide_NN
19850-5438_CD
US_FPP1
Tel_NN
:_:
1_CD
302 886 3000_CD
reporting_GER
Fax_NN
:_:
1_CD
302 886 2972_CD
Registrar_NN
and_CC
transfer_VB
office_NN
:_:
Lloyds_NN
TSB_NN
Registrars_NN
The_DT
Causeway_NN
Worthing_GER
West_NN
Sussex_NN
BN99_NN
6DA_NN
UK_NN
Tel_NN
in_PIN
the_DT
UK_NN
:_:
0870 600 3956_CD
Tel_NN
outside_PLACE
the_DT
UK_NN
:_:
44_CD
0_CD
121 433 8000_CD
Swedish_JJ
securities_NOMZ
registration_NOMZ
center_NN
:_:
VPC_NN
AB_NN
PO_NN
Box_NN
7822_CD
SE-103_NN
97_CD
Stockholm_NN
Sweden_NN
Tel_NN
:_:
46_CD
0_CD
8_CD
402_CD
9000_CD
US_FPP1
depositary_NN
:_:
JPMorgan_NN
Chase_NN
Bank_NN
PO_NN
Box_NN
43013_CD
Providence_NN
RI_NN
02940-3013_CD
US_FPP1
Tel_NN
toll_NN
free_JJ
in_PIN
the_DT
US_FPP1
:_:
888 697 8018_CD
Tel_NN
:_:
1_CD
781 575 4328_CD
